Virtual Library

Start Your Search

Tengfei Zhang



Author of

  • +

    EP1.14 - Targeted Therapy (ID 204)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Targeted Therapy
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.14-52 - Variants Distribution and Clinical Outcomes to Crizotinib According to Molecular Features in ALK-Rearranged NSCLCs (ID 2027)

      08:00 - 18:00  |  Author(s): Tengfei Zhang

      • Abstract
      • Slides

      Abstract not provided

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P1.01 - Advanced NSCLC (ID 158)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Advanced NSCLC
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/08/2019, 09:45 - 18:00, Exhibit Hall
    • +

      P1.01-36 - Clinical Potential of Tissue Tumor Mutational Burden (tTMB) and Blood TMB (bTMB) as a Biomarker in Non-Small Cell Lung Cancer (ID 2045)

      09:45 - 18:00  |  Author(s): Tengfei Zhang

      • Abstract
      • Slides

      Background

      Higher tissue TMB (tTMB) or blood TMB (bTMB) levels are associated with better response of immunotherapy in patients with non-small cell lung cancer (NSCLC). The clinical utility of bTMB and tTMB for clinical indications remain to be determined.

      Method

      Comprehensive genomic profiling were performed on 28 paired tissue and plasma samples using 520-gene panel, which has been validated to accurately reflect the actual tTMB and bTMB using in-house validation. The max allelic fraction (max.AF) of 5% in tissue and 0.5% in plasma were defined as the detection limit for TMB assessment, and samples with max.AF < 5% (n=1) in tissue and 0.5% in plasma (n=6) were excluded. Union-TMB represents the union of tTMB and bTMB, and union-TMB-class-10 denotes union-TMB of 10 is used as the cutoff for grouping.

      Result

      Correlation analysis revealed that bTMB and tTMB diaplayed significant consistency with each other (R2=0.953). Next, associations of clinical characteristics and TMB status were analyzed. Older patients were significantly associated with higher tTMB (p=0.009) than younger ones, but slightly correlated with TMB-max (p=0.055) and TMB-union (p=0.079). We also found that male patients more commonly had higher tTMB (p=0.001), bTMB (p=0.011), max-TMB (p<0.001), union-TMB (p<0.001) and union-TMB-class-10 (p=0.018) than female ones with statistical significance, while smokers usually had higher tTMB (p=0.003), max-TMB (p=0.011), union-TMB (p=0.004) and union-TMB-class-10 (p=0.044) than non-smokers. Next, the correlation between TMB and clinical response were investigated in 19 patients who received nivolumab treatment. We found patients who had partial response to nivolumab commonly had higher bTMB than those experienced stable disease or progression (p=0.076); patients with bTMB>=10 or bTMB>=16 achieved higher objective response rate (ORR) than that with bTMB<10 (42.9% vs 0.0%) or bTMB<16 (66.7% vs 10.0%); patients with squamous cell carcinoma achieved significantly favorable progression-free survival than those with adenocarcinoma (p=0.019).

      Conclusion

      We revealed that tTMB and bTMB were strongly correlated with each other for TMB assessment. Higher tTMB was strongly correlated with smokers and males compared with non-smokers and females. Higher bTMB predicted better response and ORR to nivolumab, indicating that bTMB could function as a biomarker for prognosis prediction. Prospective studies are necessary to investigate the clinical implications of tTMB and bTMB in a larger cohort of patients.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.